Schulz, Joerg B. and Rainer, Michael and Kluenemann, Hans-Hermann and Kurz, Alexander and Wolf, Stefanie and Sternberg, Kati and Tennigkeit, Frank (2011) Sustained Effects of Once-Daily Memantine Treatment on Cognition and Functional Communication Skills in Patients with Moderate to Severe Alzheimer's Disease: Results of a 16-Week Open-Label Trial. JOURNAL OF ALZHEIMERS DISEASE, 25 (3). pp. 463-475. ISSN 1387-2877,
Full text not available from this repository. (Request a copy)Abstract
The present study evaluated the effects of once-daily memantine (20 mg) treatment on cognition and communication in patients with moderate to severe Alzheimer's disease (AD). In a multicenter, single-arm open-label study, outpatients diagnosed with AD (MMSE <20; n = 97) were titrated from 5mg to 20mg once-daily memantine over 4 weeks. Once-daily memantine treatment (20 mg) was then continued for 8 weeks, followed by a 4-week wash-out period. The primary efficacy endpoint was the change from baseline in the Consortium to Establish a Registry for Alzheimer's Disease -Neuropsychological Battery (CERAD-NP) total score. Secondary efficacy endpoints included change from baseline in Functional Communication Language Inventory (FLCI) and ADCS-ADL(19) total score, and the response from baseline in Clinical Global Impression of Change (CGI-C). The CERAD-NP total score improved significantly after 12 weeks of once-daily memantine treatment compared with baseline (5.9 +/- 8.8; p < 0.0001). The FLCI total score improved significantly after 12 weeks compared with baseline (4.4 +/- 6.8; p < 0.0001). These significant improvements were already observed after 4 and 8 weeks of once-daily memantine treatment and persisted after a 4-week wash-out period. ADCS-ADL(19) total scores showed only slight increases from baseline, and CGI-C indicated that the majority of patients experienced an improvement or stabilization of the disease after 12 weeks. At least one Treatment-Emergent Adverse Event was reported by 38 (39.2%) patients. In patients with moderate to severe AD, once-daily memantine (20 mg) treatment significantly improved cognition and functional communication and was found to have a favorable safety and tolerability profile.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DOUBLE-BLIND; DONEPEZIL; CESSATION; DEMENTIA; 24-WEEK; CERAD; Alzheimer's disease; clinical trial; cognition; functional communication; memantine; once-daily; open-label |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Psychiatrie und Psychotherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 01 Jul 2020 04:53 |
| Last Modified: | 01 Jul 2020 04:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/21601 |
Actions (login required)
 |
View Item |
